A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists

The study is a global Phase III, multicenter, randomized, double-blind, placebo controlled,
parallel-group study to evaluate the safety and efficacy of omalizumab administered
subcutaneously as an add-on therapy for the treatment of adolescent and adult patients aged
12-75 who have been diagnosed with CIU who remain symptomatic despite standard-dosed H1
antihistamine treatment (including doses up to four times above the approved dose level), H2
blockers, and/or LTRA.